GenTAC Aortic Summit 2024

The Chairs of the GenTAC Aortic Summit August 29, 2024 are pleased to share our meeting program.


Our mission is to share the current knowledge of the scientific underpinnings of genetic aortic disease, to review current best practices related to diagnosis and treatment, and to foster scientific and educational exchange between scientists, institutions, lay organizations and others interested in genetic aortic conditions. Each session will have a combination of invited speakers and interesting debates.

In addition to the oral presentations and debates, we encourage abstract submissions for poster

presentation from students, early career scientists as well as experienced clinicians and scientists. We welcome abstracts utilizing mouse models advancing our understanding of HTAD as well as clinical studies.

 Topics can include but are not limited to the following:   

  • Biomarkers of Aneurysm and Dissection (Imaging or Other Types)
  • Sexual Differences in HTAD, perspectives in management and outcomes
  • Studies investigating pregnancy, post-partum complications
  • Studies in Genetics, Epigenetics and Diagnostics
  • Surgical Threshold Updates and Absolute Cutoffs for FAA, BAV, Marfan, LDS
  • New gene discoveries for HTAD
  • Therapeutics/Management Updates including Pharmacotherapy, Imaging Surveillance and Genetic Risk
  • Emergency Department Outcomes: Recognition and Management for Aortic Dissection
  • Mental Health Studies for HTAD
  • Exercise Studies, what are we learning?

IRAD/GenTAC  Abstract Guidelines


  1. Abstracts must be submitted electronically and will be due by April 15, 2024. Link for abstract submissions
  2. Abstract must be written in English.
  3. The names of the authors should be listed in the following order: Last name, first name, degree, department, institution, city, state, and country.
  4. The presenting author’s name should be underlined.
  5. The abstract should be a maximum of 300 words and include the following sections: introduction, objectives, materials and methods, results and conclusion.
  6. Please use 12 pt. Arial, single spaced, and 1” margins.
  7. Abstracts must be only 1 page and have no diagrams.
  8. There is no limit to the number of abstracts a presenter can submit.
  9. All authors will receive notification by May 1 for poster presentation.
  10. For inquiries, please contact jgrima@marfan.org.


For those whose abstracts were accepted for the IRAD/GenTAC Poster session on August 28, posters should be A0 size (841 mm x 1189 mm or 33.1 in x 46.8 in) and in portrait orientation. If desired, posters may be sent to mette@xtenso.no in Tromsø for printing and picked up before the poster session. 

Meeting Chairs:


Kim Eagle, MD 

University of Michigan 

 

Bart Loeys, MD, PhD, Co-Chair 

University of Antwerp 

 

Maral Ouzounian, MD

University of Toronto

 

William Ravekes, MD

Johns Hopkins Hospital

  

Marion Hofmann-Bowman, MD 

University of Michigan 

  

Josephine Grima, PhD 

The Marfan Foundation

unsplash